Marina Biotech, Inc. to Present at the Rodman & Renshaw 12th Annual Healthcare Conference
http://www.mdrnainc.com () —
Marina Biotech, Inc. (NASDAQ: MRNA), formerly known as MDRNA, Inc., a leading RNAi-based drug discovery and development company, announced today that it will present at the Rodman & Renshaw 12th Annual Healthcare Conference on Monday, September 13, 2010, at 3:15 p.m. Eastern Time (12:15 p.m. Pacific Time) at the New York Palace Hotel in New York City. J. Michael French, Marina Biotech President and Chief Executive Officer, will present a corporate overview and business update.
A live audio webcast will be available on the Event Calendar pages of the Investors section of the Company's website at http://www.marinabio.com (http://www.marinabio.com) . Please allow time prior to the presentation to register and download any necessary software. A replay of the presentation will be available on the Investors section of the Marina Biotech website under Event Calendar approximately one hour after the live presentation and will be archived for three months.
About Marina Biotech, Inc.
Marina Biotech (formerly known as MDRNA, Inc.) is a biotechnology company, focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina Biotech's goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com (http://www.marinabio.com) .